Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2017 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's repeatable business escalating. We need to look for management's own words conveying that the deals, orders, contracts, projects, customers, sites, or programs are individually bigger, broader, or longer than before for the same offering. Scanning the transcript: Nick Pinchuk and Aldo Pagliari discuss various segments. They talk about growth, acquisitions, product launches, etc. But do they mention that the size of individual orders, contracts, or projects is increasing? They mention "orders" at the SFC (Snap-on Franchise Conference) but that's about orders for products, not necessarily size per order. They talk about tool storage orders being up, but that's not about the size of each order. They mention "new product introductions" and "increased penetration into critical industries" but not about larger individual deals. They discuss acquisitions: Car-O-Liner, Sturtevant Richmont, BTC, Norbar. But those are acquisitions, not successive engagements of the same kind. They talk about RS&I growth, but that's revenue growth, not necessarily larger individual contracts. The question specifically asks: "does management convey that the deals, orders, contracts, projects, customers, sites, or programs it is landing NOW are individually bigger, broader, or longer than the ones it was landing for the same offering not long ago?" I don't see any such statement. They mention "broad based gains" and "double-digit increases" but that's about volume, not unit size. They mention "SNA Europe" growth for 16 quarters, but again that's overall sales growth, not about individual order size. They mention "ZEUS" launch and its success, but that's a product, not a deal size. They mention "tool storage" orders at SFC being up, but that's about the number of orders or total value, not about each order being larger. There is no mention of "average order size" or "larger contracts" or "customers starting at a higher level" etc. Thus, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.